Thyroid-immune coupling in Parkinson's disease shifts from central to peripheral control

Why thyroid findings in Parkinson's disease never converged

For years, researchers have reported contradictory thyroid profiles in Parkinson's disease. Some cross-sectional studies found decreased TSH, FT3, or FT4 in euthyroid PD patients, with lower FT3 correlating with akinetic-rigid motor subtype and greater disease severity [1]. Others found elevated FT4 and TSH in PD patients with cognitive impairment, and higher FT4 associated with poorer executive function in early PD [1]. A large retrospective cohort reported hypothyroidism associated with increased PD risk, while a prospective study found no significant difference in thyroid dysfunction prevalence between PD patients and controls [1]. Most recently, a bidirectional Mendelian randomization analysis found no causal relationship between TSH, FT4, hyperthyroidism, or hypothyroidism and PD in either direction [2]. This genetic evidence argued against a direct causal axis, yet observational associations persisted, leaving the field without a unifying explanation.

The anchor paper proposes that this inconsistency is not random variation but reflects context-dependent thyroid-immune coupling [1]. When coordinated thyroid-immune coupling is preserved, as in healthy controls, associations between thyroid indices and immune markers appear stable. When this coupling is disrupted, as the authors argue occurs in PD, thyroid indices exhibit variable and nonlinear responses to immune conditions, producing divergent patterns across study populations [1]. This interpretation reframes the question from whether thyroid dysfunction exists in PD to how thyroid regulation is modulated by the immune environment.

Central axis preserved, peripheral conversion disrupted

The anchor study analyzed 396 PD patients and 699 age- and sex-matched controls without thyroid disease, measuring TSH, FT4, FT3, total T3, total T4, and the FT3/FT4 ratio alongside CRP, lymphocyte percentage, neutrophil percentage, and NLR [1]. PD patients showed higher CRP (median 1.51 vs. 1.23 mg/L, p = 0.012), increased lymphocyte percentage, reduced neutrophil percentage, and lower NLR (1.82 vs. 2.05, p = 0.001) [1]. Critically, thyroid indices showed selective changes: total T3, total T4, FT3, and the FT3/FT4 ratio were significantly lower in PD, whereas TSH and FT4 remained within reference ranges and did not differ between groups after covariate adjustment [1]. This pattern—preserved central axis activity with altered peripheral conversion—was the first key dissociation.

The second dissociation emerged from interaction analyses. In controls, the FT3/FT4 ratio showed consistent associations with immune markers across the immune spectrum. In PD, these associations were attenuated and became dependent on immune status [1]. Generalized additive models revealed that FT3 and the FT3/FT4 ratio exhibited nonlinear declines at higher CRP levels in PD but remained relatively stable in controls [1]. Segmented regression identified a range-dependent association between neutrophil percentage and FT3/FT4 in PD, with a breakpoint indicating that the relationship changed at higher immune burden, whereas the lymphocyte-FT3/FT4 association was largely flat [1]. Group × Biomarker interactions were significant for FT3/FT4 with both lymphocyte and neutrophil percentages, but no comparable interactions were observed for TSH [1]. This pattern indicates that peripheral thyroid regulation in PD is not uniformly impaired but modulated by the immune environment in a range-dependent manner.

External validation in NHANES and the limits of cross-sectional inference

To test generalizability, the authors examined key associations in an independent population-based cohort from NHANES 2009–2010, comprising 892 participants aged 50–80 years [1]. After adjustment for age, sex, diabetes, and hypertension, TSH was not associated with NLR (β = −0.061, p = 0.236), whereas the FT3/FT4 ratio was inversely associated with NLR (β = −0.097, p < 0.001) [1]. This external validation supported the central finding: peripheral conversion indices, not central axis measures, track with immune status at the population level. The NHANES cohort also provided a comparison point for the clinical cohort findings, though it lacked PD-specific diagnoses and relied on NLR as the sole immune marker [1].

However, the retrospective, cross-sectional design of both cohorts cannot establish temporal or causal relationships between thyroid indices and immune markers [1]. Measurements were obtained from peripheral blood and may not capture tissue-specific hormone signaling or local immune activity, and data on deiodinase expression or activity were not available [1]. The study excluded individuals with known thyroid disease or thyroid-related medication use, so conclusions apply to PD patients without pre-existing thyroid conditions [1]. Residual confounding may persist despite adjustment for age, sex, BMI, diabetes, hypertension, study center, and LEDD [1]. The immune markers analyzed represent broad cellular indices and do not capture functional immune phenotypes or signaling pathways [1]. These limitations define where the conclusion stops: the findings support an association between immune status and peripheral thyroid conversion in PD, but prospective studies with longitudinal sampling and tissue-level measures are needed to clarify causality and mechanism.

How this differs from non-thyroidal illness syndrome and other competing explanations

The observed pattern shares an emphasis on peripheral thyroid hormone conversion with non-thyroidal illness syndrome (NTIS), but the overall profile differs substantially. Classical NTIS develops during acute and severe illness and is typically characterized by reduced T3, often accompanied by decreases in FT4 and suppression of TSH as disease severity progresses [1]. In the anchor cohort, TSH and FT4 remained unchanged, whereas total T3, total T4, FT3, and the FT3/FT4 ratio were reduced [1]. This profile suggests relative preservation of central thyroid regulation despite altered peripheral conversion, distinguishing it from classical NTIS. Moreover, NTIS is generally considered a continuous response that scales with illness severity, whereas the thyroid-immune relationship in PD varied across the immune spectrum, with a range-dependent association for FT3/FT4 in relation to neutrophils but no comparable pattern for lymphocytes [1]. NTIS is also regarded as a short-term, energy-conserving adaptation, whereas PD represents a chronic state of low-grade systemic stress [1]. The immune-linked changes in FT3/FT4 observed here are therefore more consistent with long-term alteration of peripheral thyroid hormone conversion than with an acute adaptive response.

Other evidence points to disrupted peripheral conversion in different contexts. In Alzheimer's disease and epilepsy, altered FT3 and T3 levels suggest disrupted peripheral conversion of T4 to T3, though the mechanisms and disease contexts differ from PD [4]. Physical activity in the general population has been negatively associated with thyroid hormone levels and inflammatory markers in NHANES data, with more active adults showing lower TSH and T4 and a blunted TSH response to reduced T4 [5]. This suggests that lifestyle factors can modulate thyroid-immune relationships even outside disease states, and raises the possibility that physical activity levels could confound or modify the associations observed in PD cohorts. The anchor study did not assess physical activity, leaving this as an open question for future research.

The immune dysregulation context in Parkinson's disease

The anchor paper's focus on thyroid-immune coupling aligns with a broader recognition that Parkinson's disease involves profound peripheral immune alterations. The immune system in PD is characterized by chronic neuroinflammation, with microglia and astrocytes responding to pathological α-synuclein, and by changes in peripheral immune cell populations including shifts in monocytes, T cells, and B cells [3]. Peripheral blood immune profiles correlate with cerebrospinal fluid immune markers and microglial activation on PET imaging, providing direct evidence for peripheral-central immune crosstalk [3]. These immune alterations are detectable in prodromal stages and are dynamic over disease progression, with shifts between innate and adaptive immune cell populations [3]. The anchor study's finding that FT3/FT4 associations with immune markers are attenuated in PD may reflect this broader immune dysregulation, where sustained immune activation disrupts normal thyroid-immune coordination.

The neutrophil-to-lymphocyte ratio, used as a composite immune marker in the anchor study, has been independently associated with dopaminergic degeneration in PD. In a study of 211 PD patients and a replication cohort of 344 de novo PD patients from PPMI, higher NLR was significantly associated with lower striatal dopamine transporter binding in the caudate and putamen, and lower lymphocyte count was associated with lower DAT levels in both cohorts [6]. This relationship was mainly driven by lymphocyte count, suggesting that peripheral immune profiles track with neurodegenerative severity. The anchor study's finding that NLR was lower in PD patients than controls (1.82 vs. 2.05, p = 0.001) appears to contrast with some prior reports of elevated NLR in PD, but the anchor cohort excluded individuals with recent infection or inflammatory conditions and adjusted for multiple covariates, which may explain the difference [1]. This discrepancy highlights the importance of cohort composition and exclusion criteria in interpreting immune marker studies.

Implications for thyroid replacement and immune intervention

The anchor study's findings suggest that thyroid replacement therapy in PD patients without overt thyroid disease may not address the underlying issue if the problem is immune-linked peripheral conversion rather than central hormone deficiency. The preservation of TSH and FT4 within reference ranges argues against central hypothyroidism, and the reduced FT3/FT4 ratio suggests that peripheral deiodinase activity may be altered by inflammatory signals [1]. The authors speculate that sustained immune activation in PD may promote D3 expression in peripheral immune cells, reducing local T3 availability and contributing to the lower FT3/FT4 ratio observed, while leaving the central HPT axis largely preserved [1]. This hypothesis is supported by experimental studies showing that innate immune cells express the full repertoire of deiodinase enzymes and that infiltrating granulocytes and macrophages upregulate D3 at inflammatory sites [1]. However, the anchor study did not measure deiodinase expression or activity, so this mechanism remains speculative.

The findings also raise questions about whether immunomodulatory interventions could restore normal thyroid-immune coupling in PD. If peripheral thyroid conversion is modulated by immune status, then treatments that reduce systemic inflammation might improve FT3/FT4 ratios and potentially affect clinical outcomes. However, the cross-sectional design cannot determine whether immune changes precede or follow thyroid alterations, and the study did not assess whether thyroid indices correlate with motor or cognitive outcomes longitudinally. The anchor study's cohort had a median disease duration of 3 years and Hoehn and Yahr stage 2, representing early to mid-stage disease [1]. Whether these patterns hold in advanced disease or in prodromal stages remains unknown. Prospective studies with longitudinal sampling, deiodinase measurements, and clinical outcome correlations are needed to translate these findings into clinical practice.

About These Sources

This research page is built on 6 peer-reviewed studies — published from 2022 to 2026, 2 from 2024 or later, 2 in Q1 journals, collectively cited 264 times — selected as the most relevant from 13 studies that passed quality screening, drawn from 134 papers retrieved from a database of over 500 million.

Sources used in this answer